Last updated 8 days ago
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
480 patients around the world
Available in Brazil, United States, Mexico
Alpine Immune Sciences Inc, A Subsidiary of Vertex
2Research sites
480Patients around the world
This study is for people with
Nephropathy
Iga nephropathy
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Diagnosed IgAN, with biopsy confirmation.24-hr proteinuria excretion ≥1.0 g/day or 24-hour uPCR ≥0.75 g/g.Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m².Stable angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARBs) as per protocol specification.
- Have received any immunosuppressive treatment or procedures (including corticosteroids, oral immunosuppressive agents, B cell or plasma cell targeted therapies, complement targeted therapies, herbal medicines per protocol, and tonsillectomy) within a wash-out period per protocol.Rapidly progressive glomerulonephritis with eGFR reduction >50% within 12 weeks of the start of screening.
Sites
Hospital Evangélico de Belo Horizonte
Recruiting
Arke Estudios Clínicos S.A. de C.V. - Veracruz
Recruiting
SponsorAlpine Immune Sciences Inc, A Subsidiary of Vertex
Study typeInterventional
Conditions
Iga nephropathy
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06564142
